Return On Equity
-162%
Third-party reference; reporting period not verified
CollPlant Biotechnologies Ltd financial metrics
Period Q4 2025 · Filed 26 Mar 2026
Key metrics snapshot
Return On Assets
-63%
Third-party reference; reporting period not verified
Operating Margin
-2438%
Third-party reference; reporting period not verified
Current Ratio
1.57x
Third-party reference; reporting period not verified
Quick Ratio
1.19x
Third-party reference; reporting period not verified
Debt-to-equity
0.9x
Third-party reference; reporting period not verified
Revenues YoY
-28%
Quarter · Through 30 Jun 2025
NetIncomeLoss YoY
20%
Quarter · Through 30 Jun 2025
Profitability
| Metric | Latest value | YoY relative change |
|---|---|---|
| Return On Equity |
-162%
Third-party reference; reporting period not verified
|
|
| Return On Assets |
-63%
Third-party reference; reporting period not verified
|
|
| Operating Margin |
-2438%
Third-party reference; reporting period not verified
|
Financial Health
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
1.57x
Third-party reference; reporting period not verified
|
|
| Quick Ratio |
1.19x
Third-party reference; reporting period not verified
|
|
| Debt-to-equity |
0.9x
Third-party reference; reporting period not verified
|
Growth
| Metric | Latest value | YoY relative change |
|---|---|---|
| Revenues YoY |
-28%
Quarter · 30 Jun 2025
|
|
| NetIncomeLoss YoY |
20%
Quarter · 30 Jun 2025
|
Share Metrics
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
12,803,006
Period-end balance · 31 Dec 2025
|
+12% |
| Common Stock, Shares, Outstanding |
12,803,006
Period-end balance · 31 Dec 2025
|
+12% |
| Common Stock, Value, Issued |
$5,492,000
Period-end balance · 31 Dec 2025
|
+10% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accounts Receivable, after Allowance for Credit Loss, Current |
$1,000
Period-end balance · 31 Dec 2025
|
-99% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax |
$969,000
Period-end balance · 31 Dec 2025
|
0% |
| Assets |
$10,785,000
Period-end balance · 31 Dec 2025
|
-42% |
| Assets, Current |
$6,747,000
Period-end balance · 31 Dec 2025
|
-49% |
| Cash and Cash Equivalents, at Carrying Value |
$5,591,000
Period-end balance · 31 Dec 2025
|
-53% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$5,591,000
Period-end balance · 31 Dec 2025
|
-53% |
| Common Stock, Par or Stated Value Per Share |
1.5
Period-end balance · 31 Dec 2025
|
0% |
| Common Stock, Shares Authorized |
30,000,000
Period-end balance · 31 Dec 2025
|
0% |
| Common Stock, Shares, Issued |
12,803,006
Period-end balance · 31 Dec 2025
|
+12% |
| Deferred Tax Assets, Gross |
$29,391,000
Period-end balance · 31 Dec 2025
|
+25% |
| Deferred Tax Assets, Operating Loss Carryforwards |
$24,515,000
Period-end balance · 31 Dec 2025
|
+31% |
| Deferred Tax Assets, Valuation Allowance |
$28,833,000
Period-end balance · 31 Dec 2025
|
+27% |
| Intangible Assets, Net (Excluding Goodwill) |
$73,000
Period-end balance · 31 Dec 2025
|
-44% |
| Inventory, Net |
$573,000
Period-end balance · 31 Dec 2025
|
+30% |
| Lessee, Operating Lease, Liability, to be Paid |
$3,189,000
Period-end balance · 31 Dec 2025
|
-12% |
| Lessee, Operating Lease, Liability, to be Paid, Year Four |
$372,000
Period-end balance · 31 Dec 2025
|
-51% |
| Lessee, Operating Lease, Liability, to be Paid, Year One |
$991,000
Period-end balance · 31 Dec 2025
|
+7% |
| Lessee, Operating Lease, Liability, to be Paid, Year Three |
$881,000
Period-end balance · 31 Dec 2025
|
+14% |
| Lessee, Operating Lease, Liability, to be Paid, Year Two |
$945,000
Period-end balance · 31 Dec 2025
|
+14% |
| Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
$343,000
Period-end balance · 31 Dec 2025
|
-37% |
| Liabilities |
$4,704,000
Period-end balance · 31 Dec 2025
|
-10% |
| Liabilities and Equity |
$10,785,000
Period-end balance · 31 Dec 2025
|
-42% |
| Liabilities, Current |
$2,672,000
Period-end balance · 31 Dec 2025
|
-10% |
| Operating Lease, Liability |
$2,846,000
Period-end balance · 31 Dec 2025
|
-7.6% |
| Operating Lease, Liability, Current |
$814,000
Period-end balance · 31 Dec 2025
|
+0.99% |
| Operating Lease, Liability, Noncurrent |
$2,032,000
Period-end balance · 31 Dec 2025
|
-11% |
| Operating Lease, Right-of-Use Asset |
$2,426,000
Period-end balance · 31 Dec 2025
|
-19% |
| Operating Lease, Weighted Average Discount Rate, Percent |
0.0778
Period-end balance · 31 Dec 2025
|
+0.13% |
| Property, Plant and Equipment, Gross |
$9,341,000
Period-end balance · 31 Dec 2025
|
+0.29% |
| Property, Plant and Equipment, Net |
$1,463,000
Period-end balance · 31 Dec 2025
|
-36% |
| Retained Earnings (Accumulated Deficit) |
$124,839,000
Period-end balance · 31 Dec 2025
|
-10% |
| Stockholders' Equity Attributable to Parent |
$6,081,000
Period-end balance · 31 Dec 2025
|
-55% |
Comparisons, sources and research notes
Sources and sharing
CLGN - CollPlant Biotechnologies Ltd Financial Facts
- Context
- Latest metrics period: Q4 2025
- Latest reported value
- Return On Equity -162%
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q4 2025
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q4 2025.
- Most recent SEC facts end date on this page: 31 Dec 2025.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for CLGN - CollPlant Biotechnologies Ltd
Latest financial period: Q4 2025. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
26 Mar 2026
Page type
Company facts
Latest period
Q4 2025
SEC-backed company facts were refreshed from filings filed on 26 Mar 2026.
Benchmark Context
How Return On Equity compares
Return On Equity does not yet have enough prior-period data for a historical comparison on this page.
Compared with
Compared with CollPlant Biotechnologies Ltd's recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Return On Equity already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q4 2025.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
How to read key metrics on this page
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
How to read Revenue on this page
Revenue is the sales a company reports from customers before most expenses are subtracted.
Why people care
People start here to understand business scale and whether demand is growing before they ask about margins or cash flow.
How to read it
Check the latest reported period first, then compare the same quarter or year against prior periods so seasonality does not distort the story.
Compare next
Compare revenue with gross profit, operating income, and operating cash flow to see whether sales are turning into healthy economics.
Revenue can jump because of acquisitions, pricing changes, or revenue-recognition rules, and reporting periods may differ across companies.
Open a live SEC-backed example
Plain-English Guide
How to read Net Income on this page
Net income is profit after operating costs, interest, taxes, and other non-operating items.
Why people care
It is the bottom-line profit figure many users recognize first, especially when they want to compare earnings with sales or cash flow.
How to read it
Use the same quarter or fiscal year comparison first, then check operating income or cash flow if the bottom line moved sharply.
Compare next
Compare it with operating income, EPS, and operating cash flow to see whether earnings are broad-based or driven by one-off items.
Net income can swing because of tax, financing, or accounting adjustments, so it is often less comparable than core operating metrics.
Open a live SEC-backed example
Filing notes and source
Key facts
- CLGN - CollPlant Biotechnologies Ltd financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q4 2025.
- Headline metric: Return On Equity -162%.
Change
- Comparable YoY change is unavailable for this metric.
- Most recent SEC facts end date: 31 Dec 2025.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2025-12-31) highlights Return On Equity -162.0%, Return On Assets -62.9%, and Operating Margin -2438.0%.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
DCF value materially below price
Overvalued
Low confidence
-3290%
fair value gap
Fair value per share
$10.84
Market price
$0.3400
CLGN - Local security
PEG ratio
n/a
Enterprise value
$137.58M
Equity value
$132.34M
DCF fair value scenarios
Bear
$7.98
- Growth
- 1%
- Discount
- 11%
- Terminal
- 2%
Gap -2449%
Base
$10.84
- Growth
- 4%
- Discount
- 10%
- Terminal
- 2.5%
Gap -3290%
Bull
$15.35
- Growth
- 7%
- Discount
- 9%
- Terminal
- 3%
Gap -4614%
Base growth: DCF Growth Assumption.
Key valuation metrics
EV/Revenue
n/a
Local security market EV / SEC revenue
Market enterprise value is unavailable
EV/EBITDA
n/a
Local security market EV / SEC EBITDA
Market enterprise value is unavailable
P/E
n/a
Local security market price / SEC EPS
Net income is unavailable or not positive
P/S
1.7x
Local security market cap / SEC revenue
P/B
0.7x
Local security market cap / SEC equity
PEG
n/a
P/E / DCF Growth Assumption
P/e or positive growth is unavailable
Core assumptions
- Projection
- 5 years
- FCF growth
- 4%
- Discount rate
- 10%
- Terminal growth
- 2.5%
SEC fact inputs
- DCF base FCF
- $9.45M
- Trailing SEC FCF
- Reported FCF
- $9.45M
- Net income
- $11.49M
- EBITDA
- $10.57M
- Cash
- $5.59M
- Debt
- $351K
- Equity
- $6.08M
- Shares
- 12,203,269
Data confidence notes
- Dcf base free cash flow: dcf base starts from trailing sec free cash flow
- Dcf base free cash flow: trailing free cash flow is not positive
- Dcf confidence is low for this sec-only free cash flow estimate
- Base free cash flow is negative; dcf output is mechanically computed but high risk
- Peg unavailable: earnings per share is not positive
Compare This Company Through SEC-backed Metrics
Use these links to compare CLGN - CollPlant Biotechnologies Ltd against other SEC filers on the same metric, then verify the company history from the paired facts page.
Revenues YoY
Latest value: -28%
NetIncomeLoss YoY
Latest value: 20%
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
45.6/100
Caution Confidence high
Return On Equity
-162%
Metric score 0.0/100
Return On Assets
-63%
Metric score 0.0/100
Financial Health
- Current Ratio
- 1.57x
- Quick Ratio
- 1.19x
- Debt to Equity
- 0.9x
Strengths
Current Ratio, Quick Ratio, and NetIncomeLoss YoY
Watchpoints
Return On Equity, Return On Assets, and Operating Margin
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first